ORIONS Money Stocks

[BioSpecialist]

CLSD close to big leg up and still trading wayy below cash

M

CLSD = Market cap $39 Mil // Cash $65 Mil //NDA acceptance within 8 days & FDA DECISION by MID YEAR for potential Blockbuster // Shares Out 32 Mil.UNDISCOVERED Stock trading almost 40% below Cash.

http://www.biotuesdays.com/briefs/2018/12/20/clearside-biomedical-submits-nda-for-xipere-in-macular-edema-associated-with-uveitis

If approved by the FDA, XIPERE would be the first therapy for macular edema associated with uveitis. The uveitis market is expected to grow to nearly $550-million in the U.S. and more than $1-billion globally by 2024.